Zydus Partners with Bioeq for US Biosimilar Rights
Published on: Dec. 23, 2025, 6:39 p.m. | Source: scanx.trade
Zydus Life Science has formed a strategic partnership with Swiss biopharmaceutical company Bioeq AG to commercialize NUFYMCO, an FDA-approved interchangeable biosimilar to Lucentis (Ranibizumab) in the US market. The US biosimilar Ranibizumab market is valued at $210.00 million. Bioeq will handle development, manufacturing, and supply, while Zydus will manage commercialization. The FDA approved NUFYMCO on December 18, 2025. This partnership aligns with Zydus's strategy to expand its US biosimilar business portfolio.
